Clinical Trial: A Study to Assess Etoricoxib Versus Diclofenac in Chinese Patients with Osteoarthritis of the Knee or Hip

This study is no longer recruiting patients.

Sponsored by: Merck
Information provided by: Merck
ClinicalTrials.gov Identifier: NCT00140972

Purpose

A Study to Assess Etoricoxib versus Diclofenac in Chinese Patients with Osteoarthritis of the Knee or Hip
Condition Intervention Phase
Osetoarthritis
 Drug: MK0633; etoricoxib
Phase IV

MedlinePlus consumer health information 

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Official Title: A Multicenter, Randomized, Parallel-Group, 4-Week, Double-Blind and Active Comparator-Controlled Study to Assess Efficacy, Safety, and Tolerability of Etoricoxib 60 Mg Once Daily Versus Diclofenac Sodium 75 Mg Twice Daily in the Treatment of Chinese Patients with Osteoarthritis of the Knee or Hip

Further Study Details: 

Study start: December 2004

Eligibility

Ages Eligible for Study:  40 Years and above,  Genders Eligible for Study:  Both
Criteria

Inclusion Criteria:

  • Chinese males or females at least 40 years of age with osteoarthritis of the knee or hip

Location Information


China
      Merck Sharp & Dohme (China) Ltd., Beijing,  100738,  China

Study chairs or principal investigators

Medical Monitor,  Study Director,  Merck   

More Information

Study ID Numbers:  2005_060
Last Updated:  August 31, 2005
Record first received:  August 30, 2005
ClinicalTrials.gov Identifier:  NCT00140972
Health Authority: China: State Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13

Resources




Common Treatments

[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Follow Us